Lumacaftor (VX-809)

Catalog No.S1565 Batch:S156507

Print

Technical Data

Formula

C24H18F2N2O5
Molecular Weight 452.41 CAS No. 936727-05-8
Solubility (25°C)* In vitro DMSO 90 mg/mL (198.93 mM)
Ethanol 4 mg/mL (8.84 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Lumacaftor (VX-809, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.
Targets
F508del-CFTR [1]
(Fisher rat thyroid cells)
0.1 μM(EC50)
In vitro

VX-809 acts at the level of the ER to allow a fraction of the F508del-CFTR to adopt a properly folded form, to exit the ER and mobilize to the cell surface for normal functioning. In Fischer rat thyroid (FRT) cells expressing F508del-CFTR, VX-809 treatment significantly improves F508del-CFTR maturation by 7.1 fold with an EC50 of 0.1 μM, and enhances F508del-CFTR-mediated chloride transport by approximately 5 fold with EC50 of 0.5 μM, while VRT-768 has higher EC50 values of 7.9 μM and 16 μM, respectively. In HEK-293 cells expressing F508del-CFTR, VX-809 (3 μM) treatment increases F508del-CFTR exit from the ER by 6 fold, reaching levels comparable to 34% of CFTR. In primary human bronchial epithelial (HBE) cells with F508del-CFTR mutation, VX-809 increases CFTR maturation and enhances chloride secretion with EC50 of 350 nM and 81 nM, respectively, more efficacious than Corr-4a and VRT-325. F508del-CFTR corrected by VX-809 exhibits single-channel open probability of 0.39 similar to normal CFTR of 0.40. Unlike VX-770, VX-809 is not a CFTR potentiator, as acute addition of VX-809 has no effect on F508del-CFTR function. In contrast to VRT-325 and Corr-4a, VX-809 does not improve the processing of the normal or mutant forms of hERG or P-gp, as well as other disease-causing mislocalized proteins, including α1-antitrypsin Z mutant (E342K-α1-AT) or N370S-β-glucosidase, suggesting that VX-809 is specific for CFTR. VX-809 in combination with VRT-325 or Corr-4a has additive effect on CFTR-mediated chloride transport in cultured F508del-HBE. [1]
In vivo

Lumacaftor (VX-809; VRT 826809) is a CFTR modulator that corrects the folding and trafficking of CFTR protein.
Features Higher specificity and efficacy relative to other CFTR defect drugs.

Protocol (from reference)

Kinase Assay:

[1]
  • F508del-CFTR maturation

    Fischer rat thyroid (FRT) cells stably expressing F508del-CFTR are treated with increasing concentrations of VX-809 for 48 hours. After incubation, cells are harvested in ice-cold D-PBS solution (without calcium and magnesium) and pelleted at 1,000 × g at 4 °C. Cell pellets are lysed in 1% Nonidet P-40, 0.5% sodium deoxycholate, 200 mM NaCl, 10 mM Tris, pH 7.8, and 1 mM EDTA plus protease inhibitor mixture (1:250) for 30 minutes on ice. Lysates are spun for 10 minutes at 10,000 × g at 4 °C to pellet nuclei and insoluble material. Approximately 12 μg total protein is heated in Laemmli buffer with 5% β-mercaptoethanol at 37 °C for 5 minutes and loaded onto a 3% to 8% Tris-acetate gel. The gel is transferred to nitrocellulose and processed for Western blotting by using monoclonal CFTR antibody or polyclonal to GAPDH. Blots are developed by enhanced chemiluminescence. Quantification of the relative amounts of bands C and GAPDH is performed by using NIH ImageJ analysis of scanned films.
Cell Assay:

[1]
  • Cell lines

    FRT (CFTR or F508del-CFTR), HEK-293 (CFTT or F508del-CFTR) , and HBE cells

  • Concentrations

    Dissolved in DMSO, final concentrations ~0.1 mM

  • Incubation Time

    24 or 48 hours

  • Method

    Cells are exposed to various concentrations of VX-809 for 24 or 48 hours. Ussing chamber techniques are used to record the transepithelial current (IT) resulting from CFTR-mediated chloride transport. The single-channel activity of CFTR is measured by using excised inside-out membrane patch recordings. Immunoblot techniques using themonoclonal CFTR antibody are used to measure CFTR maturation in FRT, HEK-293, or HBE cells expressing CFTR or F508del-CFTR.
Animal Study:

[1]
  • Animal Models

    Male Sprague– Dawley rats

  • Dosages

    1 mg/kg

  • Administration

    p.o.

References

  • https://pubmed.ncbi.nlm.nih.gov/21976485/

Customer Product Validation

<p>△F508CFTR diffusion is increased by different correction mechanisms. A, example trajectories from MDCK cell lines for wtCFTR (black) and △F508CFTR rescued by VX-809 treatment in the absence (red) and presence (blue ) of mCh-CFTR-C. B, summary graph for wtCFTR, r△F508CFTR and CFTR△PDZ diffusion in VX-809-treated and control MDCK cell lines. C, example trajectories for MDCK cells transiently expressing 3FLAG-tagged wtCFTR(black), △F508CFTR rescued by VX-809 (red), CFTR△PDZ ( blue ), and △F508CFTR△PDZ rescued by VX-809 (green). D, summary graph for CFTR dif- fusion in VX-809-treated MDCK transiently transfected with 3FLAG-tagged CFTR constructs. E, example trajectories from MDCK cell lines stably expressing wtCFTR ( left ) and △F508CFTR ( right ) treated with thapsigargin ( black)or CoPo-22 (red) or transiently expressing GFP-GRASP55 (blue ). F, graphs for △F508CFTR ( top ) and wtCFTR (bottom) diffusion in MDCK cell lines treated with thapsigargin or CoPo-22 or transiently expressing GFP-GRASP55. For reference, median and interquartile values for wtCFTR diffusive range are shown by dashed lines(bar 1, top ). G, GFP-GRASP55 is Golgi-localized by immunocytochemical analysis (scale bar, 10 μm). Scale bar in A (500 nm) refers to all trajectories. In panels Band D, statistically significant differences in populations are shown (*, p<0.001). SPT data for MDCK cell lines was derived from 140 –788 trajectories and for transiently transfected MDCK cells from 131–298 trajectories.</p>

Data from [ J Biol Chem , 2012 , 287, 43630-8 ]

<p> </p><p>VX809 inceases the expression of DF508 CFTR in oocytes.  Oocytes injected with DF508 CFTR and b-adrenergic receptor RNAs were incubated at 17oC for 3 days with and without 5 μM VX809.  The conductance at the reversal potential (gCl at Vm = Erev) was assayed using two-electrode-voltage clamp. Oocytes were placed in experimental chambers and perfused with standard Frog Ringer's at room temperature where the conductance was monitored as a function of time. The conductance was near zero before stimulation using a cocktail containing 10 μM isoproterenol and 1 μM 3-isobutyl-1-methylxanthine (hatched bar).  At steady state, conductance of oocytes treated with 5 μM VX809 ("x" symbols in panel A and white bar in panel B) was significantly larger than that of untreated oocytes ("+" symbols in panel A and black bar in panel B).  Towards the end of the experiments, oocytes were exposed to 10 μM CFTR-172 to verify that the conductance was due to CFTR chloride channels. </p>

, , Xuehong Liu of Oregon Health & Science University

<p> </p><p>Figure 7. Using chamber experiments demonstrating that TGF- β1 inhibits functional rescue of △ F508-CFTR in CF-HBE cells. Representative recordings ( A&B) demonstrating that VX-809 and CF-106951 partially rescued the CFTRinh -172 sensitive I sc compared to vehicle control (Vehicle). VX-809 (10 μM), CF-106951 (10 μM) or vehicle control (DMSO) was added to the basolateral medium for 24 h. The final concentration of DMSO was ,0.1%. Experiments were repeated at least 3 times in CF-HBE cells from 3 different donors. In subsequent experiments, corrector VX-809 ( C&D) or CF-106951 ( E&F ) was used for 24 h to rescue the CFTRinh-172 sensitive Isc. Subsequently, TGF- β1 (15 ng/ml) or vehicle control (CTRL) was added with fresh VX-809 or CF-106951 to the basolateral medium for 24 h. Monolayers were bathed in Ringer’s solution in the presence of amiloride (10 μM). TGF-β1 decreased the CFTRinh-172 sensitive Isc rescued by either VX-809 or CF-106951.</p>

,

RAF1 and CAMKK1 single siRNA validation in flow cytometry. RAF1 and CAMKK1 single Dharmacon ON-TARGETplus siRNAs with or without VX-809 treatment. Measured surface CFTR fluorescence with a BD Accuri flow cytometer with Intellicyt HTFC. The grayed out region represents VX-809s average surface fluorescence. VX-809 + siRNA significance is shown from VX-809 negative control. Data are shown as mean ± SEM (3−4 replicates). One-way ANOVA with multiple comparison for significant changes from VX-809 neg. ctrl (0 nM) (red P-values). ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05.

Data from [ , , Mol Pharm, 2018, 15(3):759-767 ]

Selleck's Lumacaftor (VX-809) Has Been Cited by 260 Publications

ACE-tRNAs are a platform technology for suppressing nonsense mutations that cause cystic fibrosis [ Nucleic Acids Res, 2025, 53(13)gkaf675] PubMed: 40650978
In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators [ Br J Pharmacol, 2025, 10.1111/bph.70176] PubMed: 40831301
Global functional genomics reveals GRK5 as a cystic fibrosis therapeutic target synergistic with current modulators [ iScience, 2025, 28(3):111942] PubMed: 40040803
Human Induced Lung Organoids: A Promising Tool for Cystic Fibrosis Drug Screening [ Int J Mol Sci, 2025, 26(2)437] PubMed: 39859153
Nasal cells as a bronchial cell surrogate for pre-clinical assessment of drug response in cystic fibrosis [ Front Pharmacol, 2025, 16:1651122] PubMed: 40978488
Inhibitors of the ubiquitin‑proteasome system rescue cellular levels and ion transport function of pathogenic pendrin (SLC26A4) protein variants [ Int J Mol Med, 2025, 55(5)69] PubMed: 40052591
The Inhibition of the Membrane-Bound Transcription Factor Site-1 Protease (MBTP1) Alleviates the p.Phe508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Defects in Cystic Fibrosis Cells [ Cells, 2024, 13(2)185] PubMed: 38247876
Comprehensive Assessment of CFTR Modulators' Therapeutic Efficiency for N1303K Variant [ Int J Mol Sci, 2024, 25(5)2770] PubMed: 38474016
Estimation of Chloride Channel Residual Function and Assessment of Targeted Drugs Efficiency in the Presence of a Complex Allele [L467F;F508del] in the CFTR Gene [ Int J Mol Sci, 2024, 25(19)10424] PubMed: 39408749
The F508del-CFTR trafficking correctors elexacaftor and tezacaftor are CFTR-independent Ca2+-mobilizing agonists normalizing abnormal Ca2+ levels in human airway epithelial cells [ Respir Res, 2024, 25(1):436] PubMed: 39702307

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.